THE PSCI PRESENTS ITS ANNUAL PUBLIC AUDIT FINDINGS REPORT, PROVIDING CONTINUED INSIGHTS INTO SUPPLIER RISKS, TRENDS, AND AREAS FOR IMPROVEMENT ACROSS THE PHARMACEUTICAL AND HEALTHCARE SUPPLY CHAIN.

Pharmaceutical and healthcare companies run thousands of audits of their suppliers’ sites annually. Audits typically require between two to four days of focused, on-site effort from both the auditor and the supplier. PSCI members work together to share these audits, in support of greater transparency and valuable efficiencies that benefit both members and suppliers.

This report shares our analysis of findings from PSCI audits available on our platform. Each year, we review these in line with the PSCI Principles to identify trends, highlight improvements, and share recommendations. PSCI work with member companies, suppliers, and regional partners to turn analysis into practical guidance, training, and peer learning that suppliers can implement quickly. Overall, this analysis provides deep insight into supplier practices within the pharmaceutical and healthcare industry and suggests where collaborative efforts will have the greatest impact, guiding us on developing targeted resources and trainings.

This year’s report analyzes 2,046 findings from 228 supplier audits uploaded to the PSCI platform in 2024. These findings are categorised into 428 Governance & Management Systems findings, 26 Ethics findings, 273 Human Rights findings, 1,098 Health & Safety findings, and 221 Environment findings, offering a comprehensive overview of supplier practices and opportunities for improvement. The report includes a summary of findings across key topics, as well as a regional analysis looking at patterns across China, India, US, Western Europe, and other regions represented in this year’s uploads, presenting recommended actions for suppliers.

What’s new this year?

• A new five-year trend analysis that shows how volumes, topics and severity have changed over time. This analysis enhances our ability to monitor momentum over time and to adapt our resources to emerging risks — supporting safer work, protected rights, and reduced environmental impact throughout the value chain.

The report identifies several key findings, including:

1. In 2024, the PSCI community uploaded more audits than ever to the PSCI platform; over 200, demonstrating great progress by PSCI’s members.
2. Health & Safety remains the largest source of findings by volume, reflecting consistent auditor focus on this business-critical and potentially life-threatening topic.
3. Governance and Management Systems increased in relative prominence since 2023, overtaking Environment as a proportion of total findings, reflecting greater auditor focus on risk management, supplier due diligence against international standards, and incident investigation expectations.
4. Human Rights findings show sharper attention to contract worker treatment and alignment with international frameworks.

The report reinforces the PSCI’s role as a catalyst for continuous improvement, equipping suppliers with tools and guidance to enhance practices and adapt to evolving demands.

For more details, access the full report here.

The SAQ/Audit & Audit Guidance sub-team have been working to update the Audit Guidance document, version 8, which is now available to download.

The main changes to the document are summarised below:

• Updated to align with the updated PSCI Principles and Strategy
• Inclusion of the digital Data Sharing via the PSCI Audit Platform
• Updated audit uploading requirements for full members
• Introduced online SAQ and removed reference of word version template
• Referenced the Audit Checklist as a separate resource in Chapter 10
• Added section on Managing Audit Related Issues in the appendix

If you have any questions regarding this update, please contact Miriam Davies.

Don’t miss this opportunity to hear from industry leaders shaping the future of resilient and sustainable supply chains

Tackling Scope 3 emissions – those indirect emissions that occur in a company’s value chain – is one of the greatest sustainability challenges facing the pharmaceutical sector. No single company can achieve Net-Zero targets alone. This panel explores how cross-industry collaboration, data transparency, and the right technology partners are helping pharma make real progress.

• How companies are overcoming barriers to sharing Scope 3 emissions data with suppliers and partners.
• Strategies for getting suppliers aligned on decarbonisation goals and reporting standards.
• A spotlight on tools like Manufacture 2030 and how they are enabling scalable, verified emissions tracking and reduction efforts.

Speakers

• Sushree Mishra, Head - Global Corporate Strategy, Corporate Communications & Inlicensing, JB Pharma
• Peylina Chu, Chair, Steering Committee, CPHI Sustainability Collective
• Ines Windisch, Head of Corporate Affairs & Sustainability, Zentiva
• Sandra Matamoros, Global Program Lead Responsible Sourcing, Grunenthal Pharma & CO KG
• Darryl Ratty, Executive Director, Global ESG, SK pharmteco

Panel Details
Panel: Collective Action, Real Results: The Power of Partnership on Scope 3 Emissions
Date: Tuesday, October 28, 2025
Time: 11:35 AM to 12:20 PM (CET)
Location: Hall 4 - 4.0G36, CPHI Frankfurt

Find out more information here.